TLPPF

PINK Telix Pharmaceuticals Limited
Sep 30, 2026 · 2:13 PM ET DELAYED Market Open

$11.26 ↓ -1.14 (-9.19%) Trading Down from the previous close of $12.40, and at the day’s high of $11.26

YTD change
+45.55%
vs 20-day SMA
-2.69%
vs 200-day SMA
+19.07%

Price ranges

Previous day
$12.40 $12.40
open $12.40 close $12.40
+$0.00 (+0.00%)
Today
$11.26 $11.26
open $11.26 now $11.26
+$0.00 (+0.00%)
Past week
$11.04 $12.55
from $12.35 now $11.26
-$1.09 (-8.83%)
Past month
$10.20 $13.00
from $11.88 now $11.26
-$0.62 (-5.22%)
This year
$5.91 $13.00
from $7.74 now $11.26
+$3.52 (+45.55%)

Price & Performance

+3.79 (+44.02%) / 6M

$8.29$9.82$11.34$12.87Mar 30Jun 30Sep 28

Signals & Sentiment

Momentum, market sentiment, and recent alerts

N/A
  • The stock is 54.7% away from all-time highs of $24.85
  • TLPPF is up 46% since the beginning of the year
  • TLPPF is up 14% over the past 12 months
  • TLPPF is down 5% over the past 1 month
  • 2% of all TLPPF investors are betting against TLPPF

TLPPF reads n/a: price sits above one of the two key moving averages, the 12-month move is +33.3%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable N/A
EPS N/A
Earnings momentum N/A Quarterly EPS growth
Quarterly change N/A

Valuation

P/E ratio N/A
Beta 0.52

Balance sheet & scale

Income$33.5K
Revenue$890.8M
Cash$251.9M
Debt$579.9K
Income / Debt 0.06×

Company & Peers

Company profile and competitor comparison

Company profile

ExchangePINK
Sector Manufacturing
Sub Sector Chemical Manufacturing
Market cap $3.8B

Telix Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development and commercialization of several clinical-stage oncology assets. The firm operates through the following segments: Therapeutics (Tx), Precision Medicine (Px), and Telix Manufacturing Solutions (TMS). The Tx segment focuses on development of targeted radionuclide therapies for urologic and neurologic oncology, and other solid tumors. The Px segment includes provision of diagnostic imaging solutions to market and expanding into new geographies and indications. The TMS segment comprises of costs to operate the firm's facilities and assets. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East and Africa. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in North Melbourne, Australia.

Competitor comparison

TickerCompany PriceChange
LLY Eli Lilly and Company $1,184.63 -0.01%
JNJ Johnson & Johnson $267.57 -1.61%
ABBV AbbVie, Inc. $263.29 -1.12%
MRK Merck & Co., Inc. $149.28 +0.40%
RHHVF Roche Holding Ltd $431.56 -2.94%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.